Charles River Laboratories International is cutting over 600 jobs, citing softening demand from pharmaceutical clients.

Charles River Laboratories has multiple sites in the Triangle area, but its local workforce has gotten smaller.

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on Charles River Labs (CRL – Research Report) today and set a price ...

After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first ...

To begin with, Charles River Laboratories International seems to have a respectable ROE. And on comparing with the industry, we found that the the average industry ROE is similar at 12%. This ...

Just a few months after the reveal of Ori Biotech’s automated cell and gene therapy manufacturing platform IRO, the technical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Charles River Laboratories (NYSE: CRL) is reducing its workforce by about 3% as part of broader cost-cutting efforts. The company, which has multiple offices in the Triangle, is a contract ...

A major bloom of blue-green algae has been discovered in part of the Charles River, prompting a public health advisory for ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Charles River and CEBINA will accelerate innovative approaches to treating neurodegenerative diseases Charles River Laboratories International, Inc. (NYSE: CRL) and CEBINA GmbH, Central European ...